These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 12828524)

  • 1. [Reversible ageusia and hyposmia induced by interferon in a patient with chronic hepatitis C].
    Irigoien Aleixandre S; Castiella Eguzkira A; Fernández Fernández FJ
    Rev Esp Enferm Dig; 2003 May; 95(5):364-8. PubMed ID: 12828524
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon alfacon-1: new preparation. Basically a me-too interferon alfa.
    Prescrire Int; 2003 Jun; 12(65):95-6. PubMed ID: 12825573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interferon therapy in chronic viral hepatitis; an autoimmunity dilemma].
    Gutkowski K; Gutkowska D; Bilkiewicz T
    Przegl Lek; 2007; 64(3):148-52. PubMed ID: 17941466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [IFN-induced anosmia y ageusia in chronic hepatitis C].
    Manzano Alonso ML; Muñoz Gómez R; Castellano Tortajada G; Solis Herruzo JA
    Gastroenterol Hepatol; 2001 Oct; 24(8):412. PubMed ID: 11674965
    [No Abstract]   [Full Text] [Related]  

  • 5. Pulmonary hypertension and hepatitis C virus related cirrhosis.
    Perrone C; Paroli M; Morelli S
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):283-4. PubMed ID: 9646225
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term outcome of chronic hepatitis C treated with interferon.
    Hadziyannis SJ; Papatheodoridis GV
    Ital J Gastroenterol Hepatol; 1999; 31(6):459-61. PubMed ID: 10575562
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of the hematologic complications of hepatitis C therapy.
    Sulkowski MS
    Clin Liver Dis; 2005 Nov; 9(4):601-16, vi. PubMed ID: 16207566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological and nonhistological criteria in the evaluation of liver involvement in chronic hepatitis C.
    Mateescu RB; Rimbaş M; Stăniceanu F; Zurac S; Dragomir P; Voiosu MR; Tătaru M; Zota M; Bucurică S
    Rom J Intern Med; 2006; 44(2):117-30. PubMed ID: 17236293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
    Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events.
    Smith JP
    Pharmacotherapy; 2008 Sep; 28(9):1151-61. PubMed ID: 18752386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis C in hemophilic patients.
    Husa P; Smejkal P; Husová L; Penka M
    Acta Virol; 2004; 48(1):35-8. PubMed ID: 15230473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comments on the paper 'The effect of a herbal medicine (Mao-to) for the prevention of interferon-induced psychiatric complications in chronic hepatitis C: a pilot study'.
    Loftis JM; Hauser P
    Hum Psychopharmacol; 2005 Apr; 20(3):211-2; author reply 213. PubMed ID: 15799008
    [No Abstract]   [Full Text] [Related]  

  • 13. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin lesions in a patient on therapy for chronic hepatitis C.
    Hisamuddin K; Veluru C; Mullen KD
    Clin Gastroenterol Hepatol; 2009 Jun; 7(6):A24. PubMed ID: 19166978
    [No Abstract]   [Full Text] [Related]  

  • 15. Massive increase of insulin resistance in a patient with chronic hepatitis C after treatment with interferon.
    Chatterjee S
    J Assoc Physicians India; 2004 Jun; 52():514. PubMed ID: 15645973
    [No Abstract]   [Full Text] [Related]  

  • 16. The prevalence and clinical characteristics of coinfection of SENV-H among Taiwanese chronic hepatitis C patients with combination therapy of high-dose interferon-alfa and ribavirin.
    Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Lin ZY; Hou NJ; Hsieh MY; Wang LY; Yu ML
    Antiviral Res; 2004 Oct; 64(1):47-53. PubMed ID: 15451178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon induced glomerular disease in a patient with chronic hepatitis C.
    Suresh RL; Suryati Y; Merican I
    Med J Malaysia; 2003 Oct; 58(4):594-6. PubMed ID: 15190636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving anti-HCV therapy.
    Pol S; Mallet VO
    Discov Med; 2006 Oct; 6(35):187-90. PubMed ID: 17234140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current treatment of chronic hepatitis C].
    Svirtlih N; Simović-Babić J; Krstić M; Delić D
    Srp Arh Celok Lek; 2005; 133(3-4):202-7. PubMed ID: 16206713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multiple extrahepatic manifestations in a patient with chronic hepatitis C treated with interferon-alfa].
    Napoli N; Tortorella C; Deramo MT; Antonaci A; Parisi CV; Antonaci S
    Recenti Prog Med; 2004 Nov; 95(11):525-8. PubMed ID: 15598090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.